Cross-sectional study on the detection of serious adverse events over the course of chemotherapy FRESH-PEF33496-en Marie-Christine PERAULT-POCHAT Cross-sectional study on the detection of serious adverse events over the course of chemotherapy SIRCADE FRESH-PEF33496-en 33496 FRESH-PEF33496 Marie-Christine PERAULT-POCHAT CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS Epidemiology France Portal (PEF) AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM) INSTITUT NATIONAL DU CANCER (INCA) null Marie-Christine;PERAULT-POCHAT Qualitative study socioanthropological serious adverse event Oncology Socio-demographic and economic determinants To evaluate the incidence of serious adverse events (SAEs) following chemotherapy and to understand the obstacles to underreporting of serious adverse events by health-care professionals. null France Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) All cases of invasive malignant tumours (malignant haemopathies and solid tumours other than basal-cell carcinomas of the skin), in situ tumours, borderline ovarian tumours and benign tumours or tumours of unknown progression of the brain and bladder. Advance colorectal adenoma is the subject of passive enrolment. Clinical data Participant-reported health data Quality of life/health perception One-time cross-sectional study Other Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Converting or copying information into a structured record Observational Study Observational Study 1000 Completed study Restricted access Contact the principal investigator Access on specific project only